CN205434422U - Drug carrier - Google Patents
Drug carrier Download PDFInfo
- Publication number
- CN205434422U CN205434422U CN201521128831.3U CN201521128831U CN205434422U CN 205434422 U CN205434422 U CN 205434422U CN 201521128831 U CN201521128831 U CN 201521128831U CN 205434422 U CN205434422 U CN 205434422U
- Authority
- CN
- China
- Prior art keywords
- macromolecule hydrogel
- utility
- model
- pharmaceutical carrier
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The utility model relates to an in the medicine field, related to a drug carrier, drug carrier comprises at least one polymer aquogel carrier unit, polymer aquogel carrier unit is rectangular, is the cross section length of its square column shape 1 20 mm, is the cross section width 1 20mm, square post height are 0.1 -, 2.0 mm, the polymer aquogel has apparent a specificality, and position of its stop in human of control that can be artificial can slow release medicine to, for general drug carrier, the utility model provides a drug carrier's medicine carrying volume is showing and is increasing.
Description
Technical field
This utility model belongs to drug world, particularly relates to a kind of pharmaceutical carrier.
Background technology
Cancer increasingly becomes the number one killer that human life is healthy, but existing antitumor drug has the biggest toxicity, can damage normal histoorgan over the course for the treatment of.For improving curative effect of medication, reduce side effects of pharmaceutical drugs, occur in that the scheme utilizing pharmaceutical carrier transmission medicine.By chemical bond or physical action packaging medicine, and ruptured or the degraded of carrier by drug diffusion, medicine marriage chain, medicine slowly discharges with given pace, reach therapeutic purposes, administration number of times can be reduced simultaneously, improve the bioavailability of medicine, thus reduce the medicine toxic and side effects to whole body.
This character having solid and liquid double grading concurrently of hydrogel is allowed to cause in drug delivery field pay close attention to widely.The mesh-structured of hydrogel can be controlled by the swellability of the degree of cross linking of hydrogel and polymer network.This structure of hydrogel can realize medicine loading in hole, and by spreading, permeating, the mode such as degraded realize the control release of medicine, the characteristic of hydrogel solid can ensure that the medicine release at the position of pathological changes simultaneously.Additionally, the environment of hydrogel aqueous solution and tissue and similar, soft, the surface of moistening and the affinity with tissue greatly reduce the material stimulation to surrounding tissue so that hydrogel has good biocompatibility.
But hydrogel drug carrier enter internal after there is no a specific aim, medicine can be discharged in whole health so that health other need not the place of medicine also by drug damages；So needing a kind of intellectual drug carrier, the off-position of this pharmaceutical carrier of manipulation that can be artificial.Additionally, the pharmaceutical pack carrying capacity of the pharmaceutical carrier of prior art is low, it is also desirable to can improve further.
Summary of the invention
The purpose of this utility model is to provide a kind of pharmaceutical carrier, it is intended to solves existing pharmaceutical carrier and discharges the problem not having specific aim to discharge.
This utility model is realized in, a kind of pharmaceutical carrier, described pharmaceutical carrier is made up of at least one macromolecule hydrogel carrier element, described macromolecule hydrogel carrier element is flat column, the cross-section lengths of its square column type is 1-20mm, cross-sectional width is 1-20mm, and square column height is 0.1 2.0mm.
Further technical scheme of the present utility model is: the kind of described macromolecule hydrogel is the one in polycaprolactone, polyurethane.This macromolecular material safety, minimum to harm.
Further technical scheme of the present utility model is: a kind of paramagnet of parcel in described macromolecule hydrogel.Reach that there is the function particularly for object by paramagnet, pharmaceutical carrier can be guided to be moved into needing the position for the treatment of then stay with this position and discharge slowly by external magnetic field in use.
Further technical scheme of the present utility model is: described paramagnet granule is ferrite particle.This is a kind of conventional paramagnet granule, less to harm.
Further technical scheme of the present utility model is: be also enclosed with antitumor drug in described macromolecule hydrogel.The effect that tumor is mainly played suppression, kills by antitumor drug.
Further technical scheme of the present utility model is: in described macromolecule hydrogel, the antitumor drug of parcel is curcumin.Curcumin is a kind of new type antineoplastic medicine, and safe toxicity is little.
Further technical scheme of the present utility model is: the composition of described ferrite particle is ferroso-ferric oxide.Ferroso-ferric oxide is conventional ferrite particle.
Further technical scheme of the present utility model is: described macromolecule hydrogel includes absorbent particles.Add absorbent particles primarily to improve the medicine carrying efficiency of pharmaceutical carrier.
Further technical scheme of the present utility model is: the absorbent particles in described macromolecule hydrogel is activated carbon granule.The adsorption effect of activated carbon is best, and avirulence.
The beneficial effects of the utility model are: described macromolecule hydrogel has significant specificity, can be artificial control its orientation stopped in human body, medicine can be discharged slowly, and, relative to general pharmaceutical carrier, the drug loading of the pharmaceutical carrier that this utility model provides significantly increases.
Accompanying drawing explanation
Fig. 1 is the schematic diagram of the pharmaceutical carrier that this utility model embodiment provides.
Reference: 1-macromolecule hydrogel carrier element；2-derivatized polymers；3-ferriferrous oxide particles；4-curcumin；5-activated carbon granule.
Detailed description of the invention
Fig. 1 shows the pharmaceutical carrier that this utility model provides, as can be seen from the figure the pharmaceutical carrier that this specific embodiment provides is made up of at least one macromolecule hydrogel carrier element 1, described macromolecule hydrogel carrier element is flat column, the cross-section lengths of its square column type is 1-20mm, cross-sectional width is 1-20mm, and square column height is 0.1 2.0mm.
The kind of described macromolecule hydrogel is the one in polycaprolactone, polyurethane.This macromolecular material safety, minimum to harm.Showing the derivatized polymers 2 of composition hydrogel in Fig. 1, but be the most with the naked eye to see that macromolecule is cancellated, picture is for convenience it is appreciated that so depict this structure.
A kind of paramagnet of parcel in described macromolecule hydrogel.Reach that there is the function particularly for object by paramagnet, pharmaceutical carrier can be guided to be moved into needing the position for the treatment of then stay with this position and discharge slowly by external magnetic field in use.
Described paramagnet granule is ferrite particle.This is a kind of conventional paramagnet granule, less to harm.
Described macromolecule hydrogel is also enclosed with antitumor drug.The effect that tumor is mainly played suppression, kills by antitumor drug.
In described macromolecule hydrogel, the antitumor drug of parcel is curcumin 4.Curcumin is a kind of new type antineoplastic medicine, and safe toxicity is little.
The composition of described ferrite particle is ferroso-ferric oxide 3.Ferroso-ferric oxide is conventional ferrite particle.
Described macromolecule hydrogel includes absorbent particles.Add absorbent particles primarily to improve the medicine carrying efficiency of pharmaceutical carrier.
Absorbent particles in described macromolecule hydrogel is activated carbon granule 5.The adsorption effect of activated carbon is best, and avirulence.
This specific embodiment provides the benefit that: described macromolecule hydrogel has significant specificity, can be artificial control its orientation stopped in human body, medicine can be discharged slowly, and, relative to general pharmaceutical carrier, the drug loading of the pharmaceutical carrier that this utility model provides significantly increases.
The foregoing is only preferred embodiment of the present utility model, not in order to limit this utility model, all any amendment, equivalent and improvement etc. made within spirit of the present utility model and principle, within should be included in protection domain of the present utility model.
Claims (2)
1. a pharmaceutical carrier, it is characterized in that described pharmaceutical carrier is made up of at least one macromolecule hydrogel carrier element, described macromolecule hydrogel carrier element is flat column, the cross-section lengths of its square column type is 1-20mm, cross-sectional width is 1-20mm, square column height is 0.1 2.0mm, wraps up paramagnet in described macromolecule hydrogel, and the kind of described macromolecule hydrogel is the one in polycaprolactone, polyurethane；Described paramagnet granule is ferrite particle；Described macromolecule hydrogel is also enclosed with antitumor drug；In described macromolecule hydrogel, the antitumor drug of parcel is curcumin；The composition of described ferrite particle is ferroso-ferric oxide；Described macromolecule hydrogel includes absorbent particles.
Pharmaceutical carrier the most according to claim 1, it is characterised in that: the absorbent particles in described macromolecule hydrogel is activated carbon granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201521128831.3U CN205434422U (en) | 2015-12-29 | 2015-12-29 | Drug carrier |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201521128831.3U CN205434422U (en) | 2015-12-29 | 2015-12-29 | Drug carrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN205434422U true CN205434422U (en) | 2016-08-10 |
Family
ID=56598858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201521128831.3U Expired - Fee Related CN205434422U (en) | 2015-12-29 | 2015-12-29 | Drug carrier |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN205434422U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106307790A (en) * | 2016-08-19 | 2017-01-11 | 安徽诺豪鞋业有限公司 | Manufacturing method for traditional Chinese medicinal controlled-release shoes |
| CN106693158A (en) * | 2016-10-19 | 2017-05-24 | 北京理工大学 | Apparatus and method for synthesizing superparamagnetic microcapsule based on microfluidic technology |
| CN107260703A (en) * | 2017-05-02 | 2017-10-20 | 北京理工大学 | A kind of internal magnetic guiding delivering method of salmonella |
-
2015
- 2015-12-29 CN CN201521128831.3U patent/CN205434422U/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106307790A (en) * | 2016-08-19 | 2017-01-11 | 安徽诺豪鞋业有限公司 | Manufacturing method for traditional Chinese medicinal controlled-release shoes |
| CN106693158A (en) * | 2016-10-19 | 2017-05-24 | 北京理工大学 | Apparatus and method for synthesizing superparamagnetic microcapsule based on microfluidic technology |
| CN107260703A (en) * | 2017-05-02 | 2017-10-20 | 北京理工大学 | A kind of internal magnetic guiding delivering method of salmonella |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dai et al. | Recent applications of immunomodulatory biomaterials for disease immunotherapy | |
| Smekalova et al. | Enhanced antibacterial effect of antibiotics in combination with silver nanoparticles against animal pathogens | |
| Huang et al. | An implantable depot that can generate oxygen in situ for overcoming hypoxia-induced resistance to anticancer drugs in chemotherapy | |
| Foley et al. | A chitosan thermogel for delivery of ropivacaine in regional musculoskeletal anesthesia | |
| de Lima et al. | Synthesis and in vivo behavior of PVP/CMC/agar hydrogel membranes impregnated with silver nanoparticles for wound healing applications | |
| CN205434422U (en) | Drug carrier | |
| WO2004105782A3 (en) | Drug delivery systems for tumor targeting ngr-molecules and uses thereof | |
| CN108042810B (en) | Acid-response hydrogen release nano-medicament and preparation method thereof | |
| CA2529742A1 (en) | Composition of a vegf antagonist and an anti-proliferative agent | |
| MX2009012279A (en) | Delivery of micro-and nanoparticles with blood platelets. | |
| WO2010136168A8 (en) | Continuous administration of cilengitide in cancer treatments | |
| MY157186A (en) | Drug delivery system for administration of poorly water soluble pharmaceutically active substances | |
| Zhang et al. | Enhanced postoperative cancer therapy by iron-based hydrogels | |
| Hussain et al. | Nanofibrous drug delivery systems for breast cancer: a review | |
| CN107349177A (en) | A kind of antitumor hydrogel of chitosan and application | |
| Wu et al. | Local anesthetic effects of lidocaine-loaded carboxymethyl chitosan cross-linked with sodium alginate hydrogels for drug delivery system, cell adhesion, and pain management | |
| Dadashi et al. | Remotely-controlled hydrogel platforms for recurrent cancer therapy | |
| Lu et al. | An overview of drug delivery nanosystems for sepsis-related liver injury treatment | |
| CN111658778B (en) | Pharmaceutical composition, preparation method and application thereof | |
| Baker | Radiation protection with nanoparticles | |
| EP2908807B1 (en) | Skin patch for absorbing toxins from the body | |
| WO2006124573A3 (en) | Treatment of cancer with 2-deoxyglucose | |
| Qian et al. | Recent advances in hydrogels for preventing tumor recurrence | |
| Prusty et al. | Nanostructured chitosan composites for cancer therapy: A review | |
| Dolati et al. | Coactive chemoradiotherapy using polysaccharides-and synthetic polymers-based hydrogels for cancer treatment: A review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160810 Termination date: 20201229 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |